Nasdaq

Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer

More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...
Nasdaq

Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 ...
FierceBiotech

FDA approves new streamlined workflow option for Roche's cobas HPV Test

New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
The American Journal of Managed Care

Roche Molecular Diagnostic's cobas HPV Test Approved by the FDA

A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...
Business Insider

Roche Granted WHO Prequalification For The Cobas HPV Test

(RTTNews) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World Health Organization (WHO) ...
FierceBiotech

Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical

ATHENA study shows the cobas HPV Test advances the standard of care by providing valuable information on the risks associated with the genotypes which cause 70 percent of cervical cancer Results from ...
Ibj.com

Roche Diagnostics hopes new self-collection HPV test will expand screening for cervical cancer risk

Roche Diagnostics is looking to a new screening tool to help women learn in a more private way if they are at increased risk for cervical cancer—a self-collection test to identify HPV. With the test, ...
MedPage Today

FDA Approves New Self-Collection Option for HPV Testing

The FDA approved a new self-collection test to detect human papillomavirus (HPV) and identify women at risk for cervical cancer, maker Roche announced on Wednesday. "HPV self-collection offers an ...
The Financial

Roche expands cobas 4800 System menu with HIV-1, HCV and HCV Genotyping Tests

The FINANCIAL — Roche announced on November 3 the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark. These new molecular diagnostic ...
GEN

Roche’s Cobas Test for Chlamydia and Gonorrhea Granted 510(k) Clearance in U.S.

Multiplex PCR Assay for cobas 4800 system uses self-collected male urine and vaginal swab samples. FDA granted 510(k) clearance for Roche’s cobas® CT/NG Test for detecting Chlamydia trachomatis (CT) ...
Pharmabiz

Roche introduces preanalytical device cobas p 480

Roche, the world's largest biotech company, has launched pre-analytical device cobas p 480 to uncover and summarize primary sample vials used in cytology-based in liquids (LBC) and molecular assays ...